Skip to Content

Rule

Food and Drug Administration Regulations; Change of Addresses; Technical Amendment

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; technical amendment.

SUMMARY:

The Food and Drug Administration (FDA) is amending its regulations to update address information for the Center for Biologics Evaluation and Research (CBER) as a result of the recent relocation of CBER offices and laboratories to the FDA White Oak campus in Silver Spring, MD, as well as make other related technical revisions. These changes are being made to ensure the accuracy of the Agency's regulations.

DATES:

This rule is effective April 3, 2015.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

John Reilly, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

FDA is amending its regulations in parts 1, 26, 99, 201, 203, 206, 207, 310, 312, 314, 600, 601, 606, 607, 610, 660, 680, 801, 807, 812, 814, 822, and 1271 (21 CFR parts 1, 26, 99, 201, 203, 206, 207, 310, 312, 314, 600, 601, 606, 607, 610, 660, 680, 801, 807, 812, 814, 822, and 1271) to reflect the following changes: (1) The relocation of CBER offices and laboratories from various Rockville and Bethesda, MD, locations to the FDA White Oak campus in Silver Spring, MD; (2) the change of address of CBER's Document Control Center; (3) updating the names of certain CBER organizational units referenced in the regulations; (4) revising certain cross-references to be more specific and thereby facilitate locating the appropriate mailing addresses for submissions, requests, and other correspondence relating to biological products regulated by CBER and the Center for Drug Evaluation and Research (CDER); and (5) making other minor changes to ensure accuracy. The updated addresses include locations to which applicants must submit information related to applications or products regulated by CBER or from which the public can request information. Where appropriate, CBER Web addresses for obtaining or submitting forms and other information are added or updated, and outdated addresses are removed. In certain instances, mail previously addressed to specific CBER offices should now be addressed to the CBER Document Control Center.

The technical amendments, reflected in the regulatory text of this final rule, are as follows:

  • In § 1.101(d)(2)(i), the CBER unit and address for submitting notifications regarding CBER-regulated products exported under section 802 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 382) are updated to the CBER Document Control Center on the White Oak campus.
  • In Appendix E to subpart A of part 26, the contact information provided for CBER, including its address, telephone, and fax numbers to be used in the two-way alert system established in accordance with the 1998 “Agreement on Mutual Recognition Between the United States of America and the European Community,” is updated to reflect CBER's move to the White Oak campus.
  • In § 99.201(c)(1), the CBER unit and address to send a submission and certification statement, or to send an application for exemption relating to the dissemination of information on an unapproved/new use regarding a biological product or device is updated to the CBER Document Control Center on the White Oak campus.
  • In § 201.25(d)(2), the CBER unit and address for submitting a request for exemption from the bar code label requirement for biological products regulated by CBER are updated to the CBER Document Control Center on the White Oak campus. Several other minor changes are made to this provision for purposes of clarity and correctness in referring to products regulated by CBER or CDER.
  • In § 201.58, the CBER unit and address for submitting a request for waiver from certain labeling requirements are updated to the CBER Document Control Center on the White Oak campus.
  • In § 203.12, the CBER unit and address for submitting an appeal from an adverse decision relating to the reimportation of biological products regulated by CBER are updated to the CBER Document Control Center on the White Oak campus. Several other minor changes in terminology also are made to this provision for purposes of accuracy and consistency when referring to products regulated by CBER or CDER.
  • In § 203.37(e), the CBER unit and address for submitting information in notifications and reports involving human prescription biological products regulated by CBER are updated to the CBER Document Control Center on the White Oak campus. Several other minor changes in terminology also are made to this provision for purposes of accuracy and consistency when referring to products regulated by CBER or CDER.
  • In § 203.70(b)(2), the CBER unit and address to apply for a reward when providing information leading to a criminal proceeding or conviction related to the sale, purchase, or trade of a drug sample are updated to the CBER Document Control Center on the White Oak campus.
  • In § 206.7(b)(1)(i), the CBER unit and address for requesting an exemption from imprinting requirements involving human drug products in solid oral dosage form are updated to the CBER Document Control Center on the White Oak campus.
  • In § 207.7(a), the CBER unit and address for submitting blood establishment registration and product listing information are updated to the CBER Document Control Center on the White Oak campus.
  • In § 310.503(f)(3), the CBER unit and address for submitting an investigational new drug (IND) application or an application for a biologics license under section 351 of the Public Health Service Act with regard to certain radioactive drugs considered biologics are updated to the CBER Document Control Center on the White Oak campus.
  • In § 312.140(a)(3), the address for submitting an IND application involving biological products regulated by CBER is updated to the White Oak campus.
  • In § 312.145(b), the CBER unit and address from which to request a list of CBER guidances are updated to the Office of Communication, Outreach and Development and the White Oak campus.
  • In § 312.310(d)(1), the CBER local telephone number for requesting emergency expanded access use of investigational biological drug products regulated by CBER is updated.
  • In § 314.440(b), the CBER addresses for submitting new drug applications and other correspondence involving certain drug products used in the collection, processing, or storage of Start Printed Page 18088blood components, as well as the address for requesting an opportunity for a hearing, are updated to the White Oak campus.
  • In § 600.2(a), the CBER Document Control Center address for regulatory submissions and other correspondence pertaining to licensed biological products regulated by CBER is updated to the White Oak campus.
  • In § 600.2(c)(1), the CBER Sample Custodian address for submitting samples and protocols of licensed biological products regulated by CBER or CDER is updated to the White Oak campus.
  • In § 600.2(c)(2), the unit and address for submitting samples and protocols of radioactive biological products are updated to the White Oak Radiation Safety Program and the White Oak campus.
  • In § 600.11(f)(6), the cross-reference “§ 600.2” is changed to “§ 600.2(a) or (b)” to provide a more specific citation to the appropriate CBER or CDER address to use when notifying FDA of certain infectious animal diseases.
  • In § 600.14(e)(1), the CBER unit and address for reporting biological product deviations for products regulated by CBER are updated to the CBER Document Control Center on the White Oak campus. The specific CBER Web address for submitting such reports electronically is removed, and a more general reference for submitting such reports electronically is added in its place.
  • In § 600.22(e), the cross-reference “§ 600.2” is changed to “§ 600.2(c)” to provide a more specific citation to the appropriate CBER or CDER address to use when submitting product or ingredient samples from an inspection of a licensed establishment.
  • In § 601.2(a), the cross-reference “§ 600.2” is changed to “§ 600.2(a) or (b)” to provide a more specific citation to the appropriate CBER or CDER address to use when submitting an application for a biologics license.
  • In § 601.12(f)(4), the reference to Form FDA 2567 (Transmittal of Labels and Circulars) is removed because the form is no longer used.
  • In § 601.15, the cross-reference “§ 600.2” is changed to “§ 600.2(c)” to provide a more specific citation to the appropriate address to use when submitting samples of imported licensed biological products regulated by CBER or CDER.
  • In § 601.28, the cross-reference “§ 600.2” is changed to “§ 600.2(a) or (b)” to provide a more specific citation to the appropriate CBER or CDER address to use when submitting postmarketing pediatric studies with regard to licensed biological products.
  • In § 601.29(b), the CBER unit and address from which to request a list of CBER guidances are updated to the White Oak campus.
  • In § 601.70(d), the cross-reference “§ 600.2” is changed to “§ 600.2(a) or (b)” to provide a more specific citation to the appropriate CBER or CDER address to use when submitting annual progress reports of postmarketing studies.
  • In § 606.170(b), the cross-reference “§ 600.2” is changed to “§ 600.2(a)” to clarify the need to use the updated CBER Document Control Center address when submitting a written report involving a fatal adverse reaction relating to blood collection or transfusion.
  • In § 606.171(e), the CBER unit and address for reporting blood and blood component product deviations are updated to the CBER Document Control Center on the White Oak Campus. The specific CBER Web address for submitting such reports electronically is removed, and a more general reference for submitting such reports electronically is added in its place. Other editorial changes have been made to improve the provision's clarity without changing its meaning.
  • In § 607.7(b) and (c), the cross-reference “§ 600.2” is changed to “§ 600.2(a)” and the reference to mail code “(HFM-375)” is removed to clarify using the updated CBER Document Control Center address in § 600.2(a) when requesting and submitting registration and product listing information with regard to the manufacture of blood products.
  • In § 607.22(a), the cross-reference “§ 600.2” is changed to “§ 600.2(a)” and the reference to mail code “(HFM-375)” is removed to clarify using the updated CBER Document Control Center address in § 600.2(a) when requesting and submitting registration and product listing information involving the manufacture of blood products on Form FDA 2830. Reference to the “Department of Health and Human Services” as part of the address has been removed.
  • Section 607.37(a) is updated to reflect that registrant and product list information filed on Form FDA 2830 for establishments manufacturing blood products, previously made available through public inspection at CBER offices, now is accessible by using CBER's Web site or by visiting FDA's Division of Dockets Management. In § 607.37(b), the name of the CBER unit and address for requesting other information regarding blood establishment registrations and blood product listings are updated to the Office of Communication, Outreach and Development and the White Oak campus.
  • In § 610.2(a) and (b), the cross-reference “§ 600.2” is changed to “§ 600.2(c)” to provide a more specific citation to the appropriate address to use when submitting samples and protocols of licensed biological products.
  • In § 610.11(g)(2), the cross-reference “§ 600.2” is changed to “§ 600.2(a) or (b)” to provide a more specific citation to the appropriate CBER or CDER address to use when submitting a request for an exemption from the general safety test requirement for licensed biological products.
  • In § 610.15(a)(3), the cross-reference “§ 600.2” is changed to “§ 600.2(a) or (b)” to provide a more specific citation to the appropriate CBER or CDER address to use when submitting data regarding the amount of aluminum used in individual doses of a biological product.
  • In § 660.3, the CBER unit and address for obtaining a Reference Hepatitis B Surface Antigen Panel have been updated to CBER Reagents and Standards Shipping and the White Oak campus.
  • In § 660.6(a)(2), the cross-reference “§ 600.2” is changed to “§ 600.2(c)” to provide a more specific citation to the appropriate address to use when submitting product samples and protocols involving Antibody to Hepatitis B Surface Antigen. Also, a misspelling of the word “Official” in the heading in § 660.6(c) is corrected.
  • In § 660.22(b), the CBER unit and address for obtaining reference preparations for Reference Blood Grouping Reagents have been updated to CBER Reagents and Standards Shipping and the White Oak campus.
  • In § 660.36, the cross-reference to § 600.2(c) is added to § 660.36(a) and (c), and the cross-reference to § 600.2(a) is added to § 660.36(b), to provide further specificity as to the appropriate address to use when submitting product samples and protocols relating to Reagent Red Blood Cells.
  • In § 660.46(a)(2), the cross-reference “§ 600.2” is changed to “§ 600.2(c)” to provide a more specific citation to the appropriate address to use when submitting product samples and protocols relating to Hepatitis B Surface Antigen.
  • In § 660.52, the CBER unit and address for obtaining reference preparations for Reference Anti-Human Globulin are updated to CBER Reagents Start Printed Page 18089and Standards Shipping and the White Oak campus.
  • In § 680.1(b)(2)(iii), (b)(3)(iv), and (c), the cross-reference “§ 600.2” is changed to “§ 600.2(a) of this chapter” to clarify using the updated CBER Document Control Center address when submitting the requested source material information regarding allergenic products.
  • In § 801.55(b)(1), the CBER unit and address for requesting an exception or alternative to a unique device identifier for devices regulated by CBER are updated to the CBER Document Control Center on the White Oak campus.
  • In § 807.90(a)(2), the address for submitting a premarket notification for devices regulated by CBER is updated to the White Oak campus; the specific CBER Web address for obtaining information about devices regulated by CBER is removed, and a more general reference for obtaining this information on the CBER's Web site is added in its place.
  • In § 812.19(a)(2), the address for sending correspondence in connection with investigational device exemptions (IDEs) involving devices regulated by CBER is updated to the White Oak campus.
  • In § 814.20(h)(2), the address for submitting a premarket approval application (PMA), a PMA amendment, a PMA supplement, or correspondence involving a PMA for devices regulated by CBER is updated to the White Oak campus.
  • In § 814.104(d)(2), the address for submitting an original PMA seeking a humanitarian device exemption (HDE), or related amendments or supplements, or other correspondence relating to an HDE for devices regulated by CBER is updated to the White Oak campus.
  • In § 822.8, the address for submitting a postmarket surveillance plan for devices regulated by CBER is updated to the White Oak campus.
  • The address for submitting a reclassification petition for devices regulated by CBER in § 860.123(b)(1) was updated to the White Oak campus in a previous FDA document published in the Federal Register on December 24, 2014 (79 FR 77387).
  • In § 1271.22(b), the CBER address and local telephone number for requesting Form FDA 3356 involving establishment registration and listing for human cells, tissues, and cellular and tissue-based products (HCT/Ps) are updated to the Document Control Center on the White Oak campus. In § 1271.22(c)(1), the CBER unit and address for submitting Form FDA 3356 are updated to the CBER Document Control Center on the White Oak campus. And in § 1271.22(c)(2), the specific CBER Web address for submitting Form FDA 3356 electronically is removed, and a more general reference for submitting this form electronically is added in its place.
  • Section 1271.37(a) is updated to reflect that registrant and product list information filed on Form FDA 3356 for HCT/Ps, previously made available for public inspection at CBER offices, can now be accessed through CBER's Web site or by visiting FDA's Division of Dockets Management. In § 1271.37(b), the name of the CBER unit and address for requesting other information regarding HCT/P establishment registrations and HCT/P listings are updated to the Office of Communication, Outreach and Development and the White Oak campus.
  • In § 1271.350(a)(5), the CBER unit and address for submitting adverse reaction reports involving an HCT/P have been updated to the CBER Document Control Center on the White Oak campus. In § 1271.350(b)(3), the address for obtaining and submitting Form FDA 3486 by mail has been updated to the CBER Document Control Center on the White Oak campus. The specific CBER Web addresses for obtaining and submitting the form electronically have been replaced by a more general reference to using CBER's electronic Web-based application.

Publication of this document constitutes final action of these changes under the Administrative Procedure Act (5 U.S.C. 553). FDA has determined that notice and public comment are unnecessary because this amendment to the regulations provides only technical changes to update addresses and other information, and is nonsubstantive.

Start List of Subjects

List of Subjects

21 CFR Part 1

  • Cosmetics
  • Drugs
  • Exports
  • Food labeling
  • Imports
  • Labeling
  • Reporting and recordkeeping requirements

21 CFR Part 26

  • Animal drugs
  • Biologics
  • Drugs
  • Exports
  • Imports

21 CFR Part 99

  • Administrative practice and procedure
  • Biologics
  • Drugs
  • Medical devices
  • Reporting and recordkeeping requirements

21 CFR Part 201

  • Drugs
  • Labeling
  • Reporting and recordkeeping requirements

21 CFR Part 203

  • Labeling
  • Prescription drugs
  • Reporting and recordkeeping requirements
  • Warehouses

21 CFR Part 206

  • Drugs

21 CFR Part 207

  • Drugs
  • Reporting and recordkeeping requirements

21 CFR Part 310

  • Administrative practice and procedure
  • Drugs
  • Labeling
  • Medical devices
  • Reporting and recordkeeping requirements

21 CFR Part 312

  • Drugs
  • Exports
  • Imports
  • Investigations
  • Labeling
  • Medical research
  • Reporting and recordkeeping requirements
  • Safety

21 CFR Part 314

  • Administrative practice and procedure
  • Confidential business information
  • Drugs
  • Reporting and recordkeeping requirements

21 CFR Part 600

  • Biologics
  • Reporting and recordkeeping requirements

21 CFR Part 601

  • Administrative practice and procedure
  • Biologics
  • Confidential business information

21 CFR Part 606

  • Blood
  • Labeling
  • Laboratories
  • Reporting and recordkeeping requirements

21 CFR Part 607

  • Blood

21 CFR Parts 610 and 660

  • Biologics
  • Labeling
  • Reporting and recordkeeping requirements

21 CFR Part 680

  • Biologics
  • Blood
  • Reporting and recordkeeping requirements

21 CFR Part 801

  • Labeling
  • Medical devices
  • Reporting and recordkeeping requirements

21 CFR Part 807

  • Confidential business information
  • Imports
  • Medical devices
  • Reporting and recordkeeping requirements

21 CFR Part 812

  • Health records
  • Medical devices
  • Medical research
  • Reporting and recordkeeping requirements

21 CFR Part 814

  • Administrative practice and procedure
  • Confidential business information
  • Medical devices
  • Medical research
  • Reporting and recordkeeping requirements

21 CFR Part 822

  • Medical devices
  • Reporting and recordkeeping requirements

21 CFR Part 1271

  • Biologics
  • Drugs
  • Human cells and tissue-based products
  • Medical devices
  • Reporting and recordkeeping requirements
End List of Subjects

Therefore, under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 1, 26, 99, 201, 203, 206, 207, 310, 312, 314, 600, 601, 606, 607, 610, 660, 680, 801, 807, 812, 814, 822, and 1271 are amended as follows:

Start Part

PART 1—GENERAL ENFORCEMENT REGULATIONS

End Part Start Amendment Part

1. The authority citation for 21 CFR part 1 continues to read as follows:

End Amendment Part Start Authority

Authority: 15 U.S.C. 1333, 1453, 1454, 1455, 4402; 19 U.S.C. 1490, 1491; 21 U.S.C. 321, 331, 332, 333, 334, 335a, 343, 350c, 350d, 352, 355, 360b, 360ccc, 360ccc-1, 360ccc-2, 362, 371, 374, 381, 382, 387, 387a, 387c, 393; 42 U.S.C. 216, 241, 243, 262, 264.

End Authority
[Amended]
Start Amendment Part

2. Section 1.101 is amended in paragraph (d)(2)(i) by removing the words “Division of Case Management (HFM-610), Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002”.

End Amendment Part Start Part

PART 26—MUTUAL RECOGNITION OF PHARMACEUTICAL GOOD MANUFACTURING PRACTICE REPORTS, MEDICAL DEVICE QUALITY SYSTEM AUDIT REPORTS, AND CERTAIN MEDICAL DEVICE PRODUCT EVALUATION REPORTS: UNITED STATES AND THE EUROPEAN COMMUNITY

End Part Start Amendment Part

3. The authority citation for 21 CFR part 26 continues to read as follows:

End Amendment Part Start Authority

Authority: 5 U.S.C. 552; 15 U.S.C. 1453, 1454, 1455; 18 U.S.C. 1905; 21 U.S.C. 321, 331, 351, 352, 355, 360, 360b, 360c, 360d, 360e, 360f, 360g, 360h, 360i, 360j, 360l, 360m, 371, 374, 381, 382, 383, 393; 42 U.S.C. 216, 241, 242l, 262, 264, 265.

End Authority Start Amendment Part

4. Appendix E to subpart A of part 26 is amended under the heading “B. For the United States:” in the entry for “Biologics” by removing the words “Director, Office of Compliance and Biologics Quality (HFM-600), 1401 Rockville Pike, Rockville, MD 20852, phone: 301-827-6190, fax: 301-594-1944” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002, telephone: 240-402-9153, FAX: 301-595-1302”.

End Amendment Part Start Part

PART 99—DISSEMINATION OF INFORMATION ON UNAPPROVED/NEW USES FOR MARKETED DRUGS, BIOLOGICS, AND DEVICES

End Part Start Amendment Part

5. The authority citation for 21 CFR part 99 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 355, 360, 360c, 360e, 360aa-360aaa-6, 371, and 374; 42 U.S.C. 262.

End Authority
[Amended]
Start Amendment Part

6. Section 99.201 is amended in paragraph (c)(1) by removing the words “the Advertising and Promotional Labeling Staff (HFM-602), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002”.

End Amendment Part Start Part

PART 201—LABELING

End Part Start Amendment Part

7. The authority citation for 21 CFR part 201 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 355, 358, 360, 360b, 360gg-360ss, 371, 374, 379e; 42 U.S.C. 216, 241, 262, 264.

End Authority
[Amended]
Start Amendment Part

8. Section 201.25 is amended in paragraph (d)(2) by removing the words “(requests involving a drug product) or to the Office of Compliance and Biologics Quality (HFM-600), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852 (requests involving a biological product)” and by adding in their place “(requests involving a drug product or biological product regulated by the Center for Drug Evaluation and Research) or to the Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002 (requests involving a biological product regulated by the Center for Biologics Evaluation and Research)”.

End Amendment Part
[Amended]
Start Amendment Part

9. Section 201.58 is amended in the second sentence by removing the words “Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Suite 200 North, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002”.

End Amendment Part Start Part

PART 203—PRESCRIPTION DRUG MARKETING

End Part Start Amendment Part

10. The authority citation for 21 CFR part 203 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 331, 333, 351, 352, 353, 360, 371, 374, 381.

End Authority Start Amendment Part

11. Section 203.12 is revised to read as follows:

End Amendment Part
An appeal from an adverse decision by the district office.

An appeal from an adverse decision by the district office involving insulin-containing drugs or human prescription drugs or biological products regulated by the Center for Drug Evaluation and Research may be made to the Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002. An appeal from an adverse decision by the district office involving human prescription biological products regulated by the Center for Biologics Evaluation and Research may be made to the Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002.

Start Amendment Part

12. Section 203.37 is amended by revising paragraph (e) to read as follows:

End Amendment Part
Investigation and notification requirements.
* * * * *

(e) Whom to notify at FDA. Notifications and reports concerning human prescription drugs or biological products regulated by the Center for Drug Evaluation and Research shall be made to the Division of Compliance Start Printed Page 18091Risk Management and Surveillance, Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002. Notifications and reports concerning human prescription biological products regulated by the Center for Biologics Evaluation and Research shall be made to the Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002.

Start Amendment Part

13. Section 203.70 is amended by revising paragraph (b)(2) to read as follows:

End Amendment Part
Application for a reward.
* * * * *

(b) * * *

(2) Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Compliance and Biologics Quality (ATTN: Director), Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002, as appropriate.

Start Part

PART 206—IMPRINTING OF SOLID ORAL DOSAGE FORM DRUG PRODUCTS FOR HUMAN USE

End Part Start Amendment Part

14. The authority citation for 21 CFR part 206 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 355, 371; 42 U.S.C. 262.

End Authority
[Amended]
Start Amendment Part

15. Section 206.7 is amended in the first sentence of paragraph (b)(1)(i) by removing the words “Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002”.

End Amendment Part Start Part

PART 207—REGISTRATION OF PRODUCERS OF DRUGS AND LISTING OF DRUGS IN COMMERCIAL DISTRIBUTION

End Part Start Amendment Part

16. The authority citation for 21 CFR part 207 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 355, 360, 360b, 371, 374, 381, 393; 42 U.S.C. 262, 264, 271.

End Authority
[Amended]
Start Amendment Part

17. Section 207.7 is amended in the first sentence of paragraph (a) by removing the words “Center for Biologics Evaluation and Research (HFM-375), 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002”.

End Amendment Part Start Part

PART 310—NEW DRUGS

End Part Start Amendment Part

18. The authority citation for 21 CFR part 310 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 355, 360b-360f, 360j, 361(a), 371, 374, 375, 379e; 42 U.S.C. 216, 241, 242(a), 262, 263b-263n.

End Authority
[Amended]
Start Amendment Part

19. Section 310.503 is amended in the last sentence of paragraph (f)(3) by removing the words “Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20014” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002”.

End Amendment Part Start Part

PART 312—INVESTIGATIONAL NEW DRUG APPLICATION

End Part Start Amendment Part

20. The authority citation for 21 CFR part 312 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 355, 360bbb, 371; 42 U.S.C. 262.

End Authority
[Amended]
Start Amendment Part

21. Section 312.140 is amended in paragraph (a)(3) by removing the words “Document Control Center (HFM-99), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002”.

End Amendment Part
[Amended]
Start Amendment Part

22. Section 312.145 is amended in the last sentence of paragraph (b) by removing the words “Office of Communication, Training, and Manufacturers Assistance (HFM-40), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Communication, Outreach and Development, 10903 New Hampshire Ave., Bldg. 71, Rm. 3103, Silver Spring, MD 20993-0002”.

End Amendment Part
[Amended]
Start Amendment Part

23. Section 312.310 is amended in the second sentence of paragraph (d)(1) by removing “301-827-1800” and by adding in its place “240-402-8010”.

End Amendment Part Start Part

PART 314—APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG

End Part Start Amendment Part

24. The authority citation for 21 CFR part 314 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 355, 356, 356a, 356b, 356c, 371, 374, 379e.

End Authority Start Amendment Part

25. Section 314.440 is amended by revising paragraph (b) introductory text to read as follows:

End Amendment Part
Addresses for applications and abbreviated applications.
* * * * *

(b) Applicants shall send applications and other correspondence relating to matters covered by this part for the drug products listed below to the Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002, except applicants shall send a request for an opportunity for a hearing under § 314.110 on the question of whether there are grounds for denying approval of an application to the Center for Biologics Evaluation and Research, ATTN: Director, at the same address.

* * * * *
Start Part

PART 600—BIOLOGICAL PRODUCTS: GENERAL

End Part Start Amendment Part

26. The authority citation for 21 CFR part 600 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 351, 352, 353, 355, 360, 360i, 371, 374; 42 U.S.C. 216, 262, 263, 263a, 264, 300aa-25.

End Authority
[Amended]
Start Amendment Part

27. Section 600.2 is amended as follows:

End Amendment Part Start Amendment Part

a. In the first sentence of paragraph (a) by removing the words “Document Control Center (HFM-99), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Start Printed Page 18092Rm. G112, Silver Spring, MD 20993-0002”.

End Amendment Part Start Amendment Part

b. In the first sentence of paragraph (c)(1) by removing the words “Sample Custodian (ATTN: HFM-672), Food and Drug Administration, Center for Biologics Evaluation and Research, Bldg. NLRC-B, Rm. 113, 5516 Nicholson Lane, Kensington, MD 20895” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, ATTN: Sample Custodian, 10903 New Hampshire Ave., Bldg. 75, Rm. G707, Silver Spring, MD 20993-0002”; and

End Amendment Part Start Amendment Part

c. In paragraph (c)(2), by removing the words “Sample Custodian (ATTN: HFM-672), Food and Drug Administration, Center for Biologics Evaluation and Research, Nicholson Lane Research Center, c/o Radiation Safety Office, National Institutes of Health, 21 Wilson Dr., Rm. 107, Bethesda, MD 20892-6780” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, ATTN: Sample Custodian, c/o White Oak Radiation Safety Program, 10903 New Hampshire Ave., Bldg. 52-72, Rm. G406A, Silver Spring, MD 20993-0002”.

End Amendment Part
[Amended]
Start Amendment Part

28. Section 600.11 is amended in paragraph (f)(6) by removing “§ 600.2” and by adding in its place “§ 600.2(a) or (b)”.

End Amendment Part Start Amendment Part

29. Section 600.14 is amended by revising paragraph (e)(1) to read as follows:

End Amendment Part
Reporting of biological product deviations by licensed manufacturers.
* * * * *

(e) Where do I report under this section? (1) For biological products regulated by the Center for Biologics Evaluation and Research (CBER), send the completed Form FDA 3486 to the CBER Document Control Center (see mailing address in § 600.2(a)), or submit electronically using CBER's electronic Web-based application.

* * * * *
[Amended]
Start Amendment Part

30. Section 600.22 is amended in paragraph (e) by removing “§ 600.2” and by adding in its place “§ 600.2(c)”.

End Amendment Part Start Part

PART 601—LICENSING

End Part Start Amendment Part

31. The authority citation for 21 CFR part 601 continues to read as follows:

End Amendment Part Start Authority

Authority: 15 U.S.C. 1451-1561; 21 U.S.C. 321, 351, 352, 353, 355, 356b, 360, 360c-360f, 360h-360j, 371, 374, 379e, 381; 42 U.S.C. 216, 241, 262, 263, 264; sec 122, Pub. L. 105-115, 111 Stat. 2322 (21 U.S.C. 355 note).

End Authority
[Amended]
Start Amendment Part

32. Section 601.2 is amended in the first sentence of paragraph (a) by removing “§ 600.2” and by adding in its place “§ 600.2(a) or (b)”.

End Amendment Part
[Amended]
Start Amendment Part

33. Section 601.12 is amended in paragraph (f)(4) by removing the words “, except that Form FDA-2567 (Transmittal of Labels and Circulars) or an equivalent form shall be used”.

End Amendment Part
[Amended]
Start Amendment Part

34. Section 601.15 is amended by removing “§ 600.2” in both places it appears and by adding in each place “§ 600.2(c)”.

End Amendment Part
[Amended]
Start Amendment Part

35. The introductory text of § 601.28 is amended by removing “§ 600.2” and by adding in its place “§ 600.2(a) or (b)”.

End Amendment Part
[Amended]
Start Amendment Part

36. Section 601.29 is amended in the last sentence of paragraph (b) by removing the words “Office of Communication, Training, and Manufacturers Assistance (HFM-40), Center for Biologics Evaluation and Research, Food and Drug Administration (see mailing addresses in § 600.2 of this chapter)” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Communication, Outreach and Development, 10903 New Hampshire Ave., Bldg. 71, Rm. 3103, Silver Spring, MD 20993-0002”.

End Amendment Part
[Amended]
Start Amendment Part

37. Section 601.70 is amended in paragraph (d) by removing “§ 600.2” and by adding in its place “§ 600.2(a) or (b)”.

End Amendment Part Start Part

PART 606—CURRENT GOOD MANUFACTURING PRACTICE FOR BLOOD AND BLOOD COMPONENTS

End Part Start Amendment Part

38. The authority citation for 21 CFR part 606 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 355, 360, 360j, 371, 374; 42 U.S.C. 216, 262, 263a, 264.

End Authority
[Amended]
Start Amendment Part

39. Section 606.170 is amended in the last sentence of paragraph (b) by removing the words “(for mailing addresses, see § 600.2 of this chapter)” and by adding in their place “(for mailing address, see § 600.2(a) of this chapter)”.

End Amendment Part Start Amendment Part

40. Section 606.171 is amended by revising paragraph (e) to read as follows:

End Amendment Part
Reporting of product deviations by licensed manufacturers, unlicensed registered blood establishments, and transfusion services.
* * * * *

(e) Where do I report under this section? You must send the completed Form FDA 3486 to the Center for Biologics Evaluation and Research (CBER), either in paper or electronic format.

(1) If you make a paper filing, send the completed form to the CBER Document Control Center (see mailing address in § 600.2(a) of this chapter), and identify on the envelope that a BPDR (biological product deviation report) is enclosed; or

(2) If you make an electronic filing, send the completed Form FDA3486 electronically using CBER's electronic Web-based application.

* * * * *
Start Part

PART 607—ESTABLISHMENT REGISTRATION AND PRODUCT LISTING FOR MANUFACTURERS OF HUMAN BLOOD AND BLOOD PRODUCTS

End Part Start Amendment Part

41. The authority citation for 21 CFR part 607 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 355, 360, 371, 374, 381, 393; 42 U.S.C. 262, 264, 271.

End Authority
[Amended]
Start Amendment Part

42. Section 607.7 is amended in paragraphs (b) and (c) by removing both times it appears “(HFM-375) (see mailing addresses in § 600.2 of this chapter)” and by adding in their place “(see mailing address in § 600.2(a) of this chapter)”.

End Amendment Part
[Amended]
Start Amendment Part

43. Section 607.22 is amended in the first sentence of paragraph (a) by removing the words “Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (HFM-375), (see mailing addresses in § 600.2 of this chapter),” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research (see mailing address in § 600.2(a) of this chapter),”.

End Amendment Part Start Amendment Part

44. Section 607.37 is revised to read as follows:

End Amendment Part
Inspection of establishment registrations and blood product listings.

(a) Any registration on Form FDA 2830 (Blood Establishment Registration and Product Listing) filed in paper or electronic format by the registrant will Start Printed Page 18093be available for inspection under section 510(f) of the act, through the Center for Biologics Evaluation and Research Blood Establishment Registration Database Web site by using the CBER electronic Web-based application or by going in person to the Food and Drug Administration, Division of Dockets Management Public Reading Room (see address in § 20.120(a) of this chapter). The following information submitted under the blood product listing requirements is illustrative of the type of information that will be available for public disclosure when it is compiled:

(1) A list of all blood products.

(2) A list of all blood products manufactured by each establishment.

(3) A list of blood products discontinued.

(4) All data or information that has already become a matter of public knowledge.

(b) Other requests for information regarding blood establishment registrations and blood product listings should be directed to the Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Communication, Outreach and Development, 10903 New Hampshire Ave., Bldg. 71, Rm. 3103, Silver Spring, MD 20993-0002.

Start Part

PART 610—GENERAL BIOLOGICAL PRODUCTS STANDARDS

End Part Start Amendment Part

45. The authority citation for 21 CFR part 610 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 355, 360, 360c, 360d, 360h, 360i, 371, 372, 374, 381; 42 U.S.C. 216, 262, 263, 263a, 264.

End Authority
[Amended]
Start Amendment Part

46. Section 610.2 is amended in the first sentence of paragraph (a) by removing “§ 600.2” and by adding in its place “§ 600.2(c)” and in the first sentence of paragraph (b) by removing “§ 600.2” and by adding in its place “§ 600.2(c) of this chapter”.

End Amendment Part
[Amended]
Start Amendment Part

47. Section 610.11 is amended in the first sentence of paragraph (g)(2) by removing “§ 600.2” and by adding in its place “§ 600.2(a) or (b)”.

End Amendment Part
[Amended]
Start Amendment Part

48. Section 610.15 is amended in paragraph (a)(3) by removing “§ 600.2” and by adding in its place “§ 600.2(a) or (b)”.

End Amendment Part Start Part

PART 660—ADDITIONAL STANDARDS FOR DIAGNOSTIC SUBSTANCES FOR LABORATORY TESTS

End Part Start Amendment Part

49. The authority citation for 21 CFR part 660 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 355, 360, 360c, 360d, 360h, 360i, 371, 372; 42 U.S.C. 216, 262, 263, 263a, 264.

End Authority
[Amended]
Start Amendment Part

50. Section 660.3 is amended by removing the words “Center for Biologics Evaluation and Research (HFM-407) (see mailing addresses in § 600.2 of this chapter)” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Reagents and Standards Shipping, 10903 New Hampshire Ave., Bldg. 75, Rm. G704, Silver Spring, MD 20993-0002”.

End Amendment Part
[Amended]
Start Amendment Part

51. Section 660.6 is amended in paragraph (a)(2) by removing “§ 600.2” and by adding in its place “§ 600.2(c)” and in the heading of paragraph (c) by removing the word “ Offical” and by adding in its place “Official”.

End Amendment Part
[Amended]
Start Amendment Part

52. Section 660.22 is amended in paragraph (b) by removing the words “Center for Biologics Evaluation and Research (HFM-407) (see mailing addresses in § 600.2 of this chapter)” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Reagents and Standards Shipping, 10903 New Hampshire Ave., Bldg. 75, Rm. G704, Silver Spring, MD 20993-0002”.

End Amendment Part
[Amended]
Start Amendment Part

53. Section 660.36 is amended as follows:

End Amendment Part Start Amendment Part

a. In paragraph (a) introductory text by removing the words “(ATTN: HFM-672) (see mailing addresses in § 600.2 of this chapter)” and by adding in their place “(see mailing addresses in § 600.2(c) of this chapter)”.

End Amendment Part Start Amendment Part

b. In paragraph (b) by adding the words “(see mailing addresses in § 600.2(a) of this chapter)” immediately following the words “Director, Center for Biologics Evaluation and Research”.

End Amendment Part Start Amendment Part

c. In paragraph (c) by adding the words “(see mailing addresses in § 600.2(c) of this chapter)” immediately following the words “Director, Center for Biologics Evaluation and Research”.

End Amendment Part
[Amended]
Start Amendment Part

54. Section 660.46 is amended in paragraph (a)(2) introductory text by removing “§ 600.2” and by adding in its place “§ 600.2(c)”.

End Amendment Part
[Amended]
Start Amendment Part

55. Section 660.52 is amended by removing the words “Center for Biologics Evaluation and Research (HFM-407) (see mailing addresses in § 600.2 of this chapter)” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Reagents and Standards Shipping, 10903 New Hampshire Ave., Bldg. 75, Rm. G704, Silver Spring, MD 20993-0002”.

End Amendment Part Start Part

PART 680—ADDITIONAL STANDARDS FOR MISCELLANEOUS PRODUCTS

End Part Start Amendment Part

56. The authority citation for 21 CFR part 680 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371; 42 U.S.C. 216, 262, 263, 263a, 264.

End Authority
[Amended]
Start Amendment Part

57. Section 680.1 is amended as follows:

End Amendment Part Start Amendment Part

a. In the last sentence of paragraph (b)(2)(iii) by removing the words “addresses in § 600.2” and by adding in their place “address in § 600.2(a) of this chapter”.

End Amendment Part Start Amendment Part

b. In paragraph (b)(3)(iv) by removing the word “allergenic” and by adding in its place the word “Allergenic” and by removing the words “addresses in § 600.2” and by adding in their place “address in § 600.2(a) of this chapter”.

End Amendment Part Start Amendment Part

c. In paragraph (c) by removing the words “addresses in § 600.2” and by adding in their place “address in § 600.2(a) of this chapter”.

End Amendment Part Start Part

PART 801—LABELING

End Part Start Amendment Part

58. The authority citation for 21 CFR part 801 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 360i, 360j, 371, 374.

End Authority
[Amended]
Start Amendment Part

59. Section 801.55 is amended in paragraph (b)(1) by removing the words “Office of Communication, Outreach and Development (HFM-40), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002”.

End Amendment Part Start Part Start Printed Page 18094

PART 807—ESTABLISHMENT REGISTRATION AND DEVICE LISTING FOR MANUFACTURERS AND INITIAL IMPORTERS OF DEVICES

End Part Start Amendment Part

60. The authority citation for 21 CFR part 807 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 360, 360c, 360e, 360i, 360j, 371, 374, 381, 393; 42 U.S.C. 264, 271.

End Authority
[Amended]
Start Amendment Part

61. Section 807.90 is amended in paragraph (a)(2) by removing in the first sentence the words “Document Control Center (HFM-99), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002” and by removing in the second sentence “at http://www.fda.gov/​cber/​dap/​devlst.htm” and by adding in its place “by using the Center for Biologics Evaluation and Research electronic Web-based application”.

End Amendment Part Start Part

PART 812—INVESTIGATIONAL DEVICE EXEMPTIONS

End Part Start Amendment Part

62. The authority citation for 21 CFR part 812 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 331, 351, 352, 353, 355, 360, 360c-360f, 360h-360j, 371, 372, 374, 379e, 381, 382, 383; 42 U.S.C. 216, 241, 262, 263b-263n.

End Authority
[Amended]
Start Amendment Part

63. Section 812.19 is amended in paragraph (a)(2) by removing the words “Document Control Center (HFM-99), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002”.

End Amendment Part Start Part

PART 814—PREMARKET APPROVAL OF MEDICAL DEVICES

End Part Start Amendment Part

64. The authority citation for 21 CFR part 814 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 351, 352, 353, 360, 360c-360j, 371, 372, 373, 374, 375, 379, 379e, 381.

End Authority
[Amended]
Start Amendment Part

65. Section 814.20 is amended in paragraph (h)(2) by removing the words “Document Control Center (HFM-99), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002”.

End Amendment Part
[Amended]
Start Amendment Part

66. Section 814.104 is amended in paragraph (d)(2) by removing the words “Document Control Center (HFM-99), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002”.

End Amendment Part Start Part

PART 822—POSTMARKET SURVEILLANCE

End Part Start Amendment Part

67. The authority citation for 21 CFR part 822 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 331, 352, 360i, 360l, 371, 374.

End Authority
[Amended]
Start Amendment Part

68. Section 822.8 is amended by removing the words “Document Control Center (HFM-99), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002”.

End Amendment Part Start Part

PART 1271—HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS

End Part Start Amendment Part

69. The authority citation for 21 CFR part 1271 continues to read as follows:

End Amendment Part Start Authority

Authority: 42 U.S.C. 216, 243, 263a, 264, 271.

End Authority
[Amended]
Start Amendment Part

70. Section 1271.22 is amended as follows:

End Amendment Part Start Amendment Part

a. In paragraph (b)(1) by removing the words “Center for Biologics Evaluation and Research (HFM-775), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, Attention: Tissue Establishment Registration Coordinator” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002, ATTN: Tissue Establishment Registration Coordinator”.

End Amendment Part Start Amendment Part

b. In paragraph (b)(3) by removing “301-827-1800” and by adding in its place “240-402-8010”.

End Amendment Part Start Amendment Part

c. In paragraph (c)(1) by removing the words “Center for Biologics Evaluation and Research (HFM-775), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, Attention: Tissue Establishment Registration Coordinator” and by adding in their place the words “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002, ATTN: Tissue Establishment Registration Coordinator”.

End Amendment Part Start Amendment Part

d. In paragraph (c)(2) by removing “at http://www.fda.gov/​cber/​tissue/​tisreg.htm” and by adding in its place the words “using the CBER electronic Web-based application”.

End Amendment Part Start Amendment Part

71. Section 1271.37 is revised to read as follows:

End Amendment Part
Will establishment registrations and HCT/P listings be available for inspection, and how do I request information on registrations and listings?

(a) Any registration on Form FDA 3356 filed in paper or electronic format by each establishment will be available for public inspection through the Center for Biologics Evaluation and Research Human Cell and Tissue Establishment Registration—Public Query Web site by using the CBER electronic Web-based application or by going in person to the Food and Drug Administration, Division of Dockets Management Public Reading Room (see address in § 20.120(a) of this chapter). The following information submitted under the HCT/P requirements is illustrative of the type of information that will be available for public disclosure when it is compiled:

(1) A list of all HCT/P's;

(2) A list of all HCT/P's manufactured by each establishment;

(3) A list of all HCT/P's discontinued; and

(4) All data or information that has already become a matter of public record.

(b) You should direct your other requests for information regarding HCT/P establishment registrations and HCT/P listings to the Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Communication, Outreach and Development, 10903 New Hampshire Start Printed Page 18095Ave., Bldg. 71, Rm. 3103, Silver Spring, MD 20993-0002.

Start Amendment Part

72. Section 1271.350 is amended:

End Amendment Part Start Amendment Part

a. In the first sentence of paragraph (a)(5) by removing the words “Center for Biologics Evaluation and Research (HFM-210), Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448” and by adding in their place “Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002”; and

End Amendment Part Start Amendment Part

b. By revising paragraph (b)(3) to read as follows:

End Amendment Part
Reporting.
* * * * *

(b) * * *

(3) You must report each such HCT/P deviation that relates to a core CGTP requirement on Form FDA 3486 within 45 days of the discovery of the event either electronically using the Center for Biologics Evaluation and Research electronic Web-based application or by mail to the Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002.

Start Signature

Dated: March 23, 2015.

Leslie Kux,

Associate Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2015-07268 Filed 4-2-15; 8:45 am]

BILLING CODE 4164-01-P